Verseon (LSE:VERS) Other Gross PPE : £41.71 Mil (As of Jun. 2019)

View and export this data going back to 2015. Start your Free Trial

What is Verseon Other Gross PPE?

Verseon's Other Gross PPE for the quarter that ended in Jun. 2019 was £41.71 Mil.

Verseon's quarterly Other Gross PPE increased from Jun. 2018 (£34.32 Mil) to Dec. 2018 (£40.17 Mil) and increased from Dec. 2018 (£40.17 Mil) to Jun. 2019 (£41.71 Mil).

Verseon's annual Other Gross PPE increased from Dec. 2016 (£16.77 Mil) to Dec. 2017 (£28.58 Mil) and increased from Dec. 2017 (£28.58 Mil) to Dec. 2018 (£40.17 Mil).

Verseon Other Gross PPE Historical Data

The historical data trend for Verseon's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verseon Other Gross PPE Chart

Verseon Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Other Gross PPE

Get a 7-Day Free Trial

6.12

16.77

28.58

40.17

Verseon Semi-Annual Data
	Dec11	Dec12	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19
Other Gross PPE	Get a 7-Day Free Trial									22.33	28.58	34.32	40.17	41.71

Verseon Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Verseon (LSE:VERS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verseon Corp (LSE:VERS) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

N/A

Address

47071 Bayside Parkway, Fremont, CA, USA, 94538

Website

http://www.verseon.com

Verseon Corp is a part of the healthcare sector in the United States. It is a technology-based pharmaceutical company with a computer-driven drug discovery platform. The company designs novel drug candidates that are unlikely to be found using conventional methods. It is also engaged in drug discovery programs such as the diabetic macular edema product candidates, which treat the diseases by controlled disruption of the kallikrein kinin cascade.